Premium
Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management
Author(s) -
Varvaresou Athanasia,
Iakovou Kriton,
Mellou Fotini,
Myrogiannis Dimetrios,
Papageorgiou Spyros
Publication year - 2020
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.13211
Subject(s) - medicine , adverse effect , targeted therapy , dermatology , oncology , chemotherapy , pharmacology , cancer
Background Numerous oncology patients who receive targeted therapy suffer from the skin adverse effects induced. Novel agents, that is tyrosine kinase inhibitors and RAS‐RAF‐MEK‐ERK pathway, have given good results in patient survival while decreasing the systemic toxicities in comparison to conventional cytotoxic chemotherapy, but are also related to skin adverse effects. Aims In this article, we highlighted the importance of specific pharmaceutical and dermocosmetic management of the untoward events of targeted therapy. Conclusion The combination of Oncodermatology, Psychodermatology, Cosmetic Dermatology, Cosmetic Science, Dermatopharmacology and Aesthetic Science can offer a lot for the prevention or early relief of the cutaneous adverse effects in oncology patients receiving targeted therapy.